Table 3 Demographic data of clinical cases, diagnoses and pathologic findings
Age | Gender | Primary Diagnosis | Secondary Diagnosis | Thal Phase (A score) | Braak stage (B score) | CERAD (C score) | |
|---|---|---|---|---|---|---|---|
AD | 78 | female | ADNC, high | CAA | 4 (A3) | VI (B3) | frequent (C3) |
AD | 64 | female | ADNC, high | CAA | 4 (A3) | VI (B3) | frequent (C3) |
AD | 77 | male | ADNC, high | ARTAG; CAA | 4 (A3) | VI (B3) | moderate (C2) |
AD | 64 | male | ADNC, high | CAA | 5 (A3) | VI (B3) | frequent (C3) |
AD | 68 | male | LBD (neocortical) | ADNC, intermediate | 3 (A2) | V (B3) | frequent (C3) |
DLB | 81 | female | ADNC, high | LBD (neocortical); CAA | 4 (A3) | VI (B3) | frequent (C3) |
DLB | 68 | female | LBD (neocortical) | ADNC, high; CAA; LATE stage1 | 5 (A3) | V (B3) | frequent (C3) |
DLB | 83 | male | ADNC, intermediate | LBD (neocortical); CAA; LATE stage 2 | 3 (A2) | V (B3) | frequent (C3) |
PSP | 63 | female | FTLD-tau (PSP) | 0 (A0) | 0 (B0) | none (C0) | |
PSP | 69 | female | FTLD-tau (PSP) | ADNC, low | 3 (A2) | III (B2) | none (C0) |
PSP | 72 | female | FTLD-tau (PSP) | PART (Braak II) | 0 (A0) | II (B1) | none (C0) |
PSP | 78 | male | FTLD-tau (PSP) | 0 (A0) | 0 (B0) | none (C0) | |
PSP | 77 | male | FTLD-tau (PSP) | ADNC, low; CAA | 2 (A1) | II (B1) | none (C0) |
CBD | 73 | female | FTLD-tau (CBD) | ADNC, low; CAA | 1 (A1) | II (B1) | none (C0) |
CBD | 70 | male | FTLD-tau (CBD) | ADNC, low; CAA | 3 (A2) | II (B1) | none (C0) |